Loading...
XHKG
0460
Market cap1.64bUSD
Jul 18, Last price  
1.39HKD
1D
-2.11%
1Q
120.63%
Jan 2017
-35.65%
IPO
-50.71%
Name

Sihuan Pharmaceutical Holdings Group Ltd

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
6.18
EPS
—
Div Yield, %
1.51%
Shrs. gr., 5y
-0.43%
Rev. gr., 5y
-7.96%
Revenues
1.90b
+2.18%
161,776,000286,349,000510,048,000708,907,0001,036,881,0002,242,063,0003,042,531,0004,732,700,0003,084,236,0003,167,211,0003,185,699,0002,745,809,0002,917,405,0002,878,318,0002,464,226,0003,038,391,0002,181,189,0001,860,539,0001,901,109,000
Net income
-217m
L+301.10%
90,453,000179,266,000237,059,000326,316,000522,065,000824,048,000904,402,0001,303,012,0001,671,281,0002,062,378,0001,708,239,0001,448,935,0001,619,956,000-2,709,364,000473,382,000416,509,000-1,951,214,000-54,017,000-216,662,000
CFO
0k
-100.00%
75,980,000182,263,000261,169,000385,648,000380,101,000712,934,0001,046,064,0001,510,633,0001,760,936,0001,568,610,0002,018,026,0001,917,590,0001,792,794,0001,417,858,000227,131,000665,293,00046,493,000199,487,0000
Dividend
Sep 27, 20240.021 HKD/sh
Earnings
Aug 28, 2025

Profile

Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in the People's Republic of China. It offers drugs in the oncology, metabolic diseases, digestive system, and other therapeutic areas. The company is also involved in the investment and sale of medical beauty products; manufacture of medical instruments; investment in properties; construction for medical projects; and project preparation for pharmaceutical products manufacturing. In addition, it provides information support, general hospital, hospital management, biotechnology promotion, and medical aesthetic research and development services. The company was founded in 2001 and is based in Wanchai, Hong Kong.
URL
http://www.sihuanpharm.com/
IPO date
Oct 28, 2010
Employees
3,241
Domiciled in
CN
Incorporated in
BM

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,901,109
2.18%
1,860,539
-14.70%
2,181,189
-28.21%
Cost of revenue
2,338,899
2,068,120
2,792,387
Unusual Expense (Income)
NOPBT
(437,790)
(207,581)
(611,198)
NOPBT Margin
Operating Taxes
43,261
96,427
196,794
Tax Rate
NOPAT
(481,051)
(304,008)
(807,992)
Net income
(216,662)
301.10%
(54,017)
-97.23%
(1,951,214)
-568.47%
Dividends
(298,560)
(1,315,530)
Dividend yield
4.94%
14.84%
Proceeds from repurchase of equity
(33,811)
BB yield
0.56%
Debt
Debt current
183,354
299,642
340,259
Long-term debt
818,849
999,676
907,712
Deferred revenue
5,660
Other long-term liabilities
1,512,386
1,334,589
(104,700)
Net debt
(3,448,800)
(3,483,242)
(4,451,218)
Cash flow
Cash from operating activities
199,487
46,493
CAPEX
(125,346)
(402,459)
Cash from investing activities
169,877
(1,661,121)
Cash from financing activities
(419,561)
(238,934)
FCF
(273,832)
381,071
(242,398)
Balance
Cash
3,632,961
4,367,682
4,791,851
Long term investments
818,042
414,878
907,338
Excess cash
4,355,948
4,689,533
5,590,130
Stockholders' equity
1,121,109
1,288,531
2,671,377
Invested Capital
6,283,346
6,439,739
7,109,531
ROIC
ROCE
EV
Common stock shares outstanding
9,265,984
9,297,073
9,329,999
Price
0.66
1.54%
0.65
-31.58%
0.95
-35.81%
Market cap
6,115,549
1.20%
6,043,097
-31.82%
8,863,499
-36.85%
EV
3,243,795
3,653,995
6,228,964
EBITDA
(437,790)
18,652
(272,425)
EV/EBITDA
195.90
Interest
269,337
211,176
Interest/NOPBT